Lazertinib as a Frontline Treatment in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancer: Results from the Phase I/II Trial

B. C. Cho,J. -Y. Han, K. H. Lee,Y. -G. Lee,D. -W. Kim, Y. J. Min,S. -W. Kim, E. K. Cho, J. -H. Kim,G. -W. Lee,S. S. Lee,N. M. Lee, H. W. Jang,M. -J. Ahn

JOURNAL OF THORACIC ONCOLOGY(2022)

Cited 0|Views4
No score
Key words
Lazertinib, NSCLC, EGFR-TKI
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined